藻類在疫苗上的發展 - tfrin.gov.t administration, fda) 於2006 年雖已核可此...
Post on 31-Aug-2019
3 Views
Preview:
TRANSCRIPT
-
(Elizabeth et al.,
2014)
DNA
4
DNA
anti-DNA
(Newcastle disease virus, NDV)
(Food and Drug
Administration, FDA) 2006
(Rybicki,
2009)
(gut-associated lymphoid tissue) (Kwon et al.,
2013)
(total soluble protein, TSP) 1%
(recombinant viral vectors)
(Agrobacterium)
(Rybicki, 2009)
-
(protein
folding) (Chebolu et al., 2009)
10% (Manuell et al.,
2007; Surzycki et al., 2009)
(Chlamydomonas reinhardtii)
(vascular endothelial growth factor)
(Rasala et al., 2010)
(codon optimization)
(Franklin et al., 2002;
Surzycki et al., 2009) FDA
(generally recognized as
safe)
(homoplasmid)
620
(Gregory et al., 2013)
VP1 B
(fusion protein)
34% (classical
swine fever virus, CSFV) E2
(Sun et al., 2003)
DNA
DNA
DNA
(white spot syndrome virus) VP28
(Surzycki et al., 2009)
(glycosylation)
top related